|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1992-06-19 |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
一项非那雄胺喷雾剂(CU-40102)在中国成年男性雄激素性秃发(AGA)患者中的多中心、随机、双盲和安慰剂对照的有效性和安全性的Ⅲ期临床研究
主要目的,与安慰剂对比,评估CU-40102治疗中国成年男性AGA长达24周的有效性
次要目的,与安慰剂对比,评估CU-40102治疗中国成年男性AGA长达24周的安全性
A Randomized, Doubleblind, Vehicle-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Tolerability of P-3073 for Topical Treatment of Nail Psoriasis
The objective of this phase III study is to evaluate the efficacy, systemic safety and local tolerability of P-3073 (calcipotriene 0.005%) nail solution in patients with mild to moderate psoriatic fingernail/s.
A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis
The aim of this phase III study is to establish the efficacy and safety of P-3058 (terbinafine 10% nail solution) topically administered once weekly in patients with onychomycosis in comparison to the Vehicle in a double-blind fashion. The overall treatment period will be of 48 weeks.
100 项与 Polichem SA (Switzerland) 相关的临床结果
0 项与 Polichem SA (Switzerland) 相关的专利(医药)
100 项与 Polichem SA (Switzerland) 相关的药物交易
100 项与 Polichem SA (Switzerland) 相关的转化医学